Nearly 60 Scientific Research Results of Innovative Pharmaceutical Companies on the STAR Market Attract Global Attention

From June 12 to 15, the European Hematology Association (EHA) Annual Meeting 2025 was held in Milan, Italy. This is one of the most influential academic events in the global field of hematology. At the meeting, nearly 60 clinical research outcomes from 4 innovative pharmaceutical companies on the STAR Market, BeiGene, Dizal Pharmaceutical, InnoCare Pharma, and Chipscreen Biosciences, were showcased. Among them, 4 studies were selected for oral presentations, and 14 studies were chosen for poster sessions, highlighting China's scientific strength in the development of innovative therapies for hematological tumors.

In recent years, the cluster breakthroughs of innovative pharmaceutical companies from the STAR Market on prestigious international stages like ASCO and EHA signify that China's innovative pharmaceutical industry has entered the fast track of strategic transformation from "rapidly following" to "independent innovation". With continuous innovation and exploration in cutting-edge fields and clinical development capabilities for efficient commercialization, Chinese companies are rapidly emerging in the global field of innovative hematology treatments, and are likely to promote more China's solutions to become the new benchmark in international hematology diagnosis and treatment guidelines.

The above information is provided for reference purposes only and does not constitute investment advice.